Janssen Biotech Inc.

20/08/2024 | Press release | Distributed by Public on 20/08/2024 13:56

RYBREVANT® (amivantamab vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first line chemotherapy free treatment for patients with EGFR mutated advanced lung cancer